Artificial intelligence for clinical research: a paradigm shift
Artificial intelligence for clinical research are increasingly intertwined as the pharmaceutical sector faces major structural challenges: growing protocol complexity, patient recruitment difficulties, exponential data growth, and mounting pressure on timelines and costs. In this context, artificial intelligence (AI) is progressively emerging as a strategic lever to accelerate, secure and optimise the clinical development of medicinal products.
Contrary to common misconceptions, AI does not aim to replace human expertise. Instead, it enhances the analytical, predictive and decision-making capabilities of clinical research stakeholders, while respecting strict regulatory and ethical requirements.
Where does AI concretely intervene in clinical research?
1. Accelerating clinical trial design
One of the most significant contributions of artificial intelligence and clinical research lies in protocol design.
Machine learning algorithms are capable of:
- analysing thousands of previous clinical trials (public databases, scientific publications),
- identifying the most relevant inclusion and exclusion criteria,
- simulating alternative study design scenarios.
These approaches help reduce the number of protocol amendments, which remain one of the leading causes of delays and cost overruns in clinical trials.
The European Medicines Agency (EMA) highlights in several reflection documents that AI-based methods may contribute to improving the efficiency of clinical development, provided that robust governance and oversight mechanisms are in place.
2. Optimising patient recruitment and retention
Patient recruitment accounts for more than 30% of clinical trial delays, according to several international analyses. Artificial intelligence offers multiple opportunities to address this bottleneck:
- automated identification of eligible patients from electronic health records,
- cross-referencing of clinical, biological and demographic datasets,
- prediction of non-adherence risks or potential loss to follow-up.
These approaches are particularly relevant in the context of decentralised clinical trials (DCTs), which have gained momentum since the COVID-19 crisis.
The Food and Drug Administration (FDA) acknowledges that digital and algorithmic tools can improve diversity and representativeness in clinical trial populations, provided that strict methodological controls are applied.
Source:
https://www.iconplc.com
3. Leveraging large-scale clinical data
Modern clinical research increasingly relies on diversified and complex data sources:
- traditional interventional clinical trial data,
- Real-World Data (RWD),
- data from connected devices and digital health tools,
- medical imaging, genomic data and biomarkers.
Artificial intelligence enables the processing of massive, heterogeneous datasets, facilitating the identification of weak signals and the generation of clinical hypotheses more rapidly than traditional statistical methods.
Peer-reviewed publications in Nature Medicine and The Lancet Digital Health demonstrate that AI-driven algorithms can enhance early detection of adverse events and help identify responder subgroups within heterogeneous patient populations.
These developments illustrate how artificial intelligence for clinical research are progressively reshaping evidence generation strategies.
4. Strengthening trial monitoring and pharmacovigilance
During trial conduct, AI can be used for:
- automated detection of data anomalies,
- early identification of safety signals,
- enhanced monitoring of adverse events.
These applications are fully aligned with the objectives of Regulation (EU) No 536/2014 on clinical trials, which aims to strengthen quality, transparency and patient safety, notably through the Clinical Trials Information System (CTIS).
By integrating AI tools within monitoring processes, sponsors and CROs can improve risk anticipation and ensure more proactive pharmacovigilance.
Artificial intelligence for clinical research: regulatory and ethical challenges
While the benefits of artificial intelligence for clinical research are significant, their implementation raises major regulatory and ethical questions:
- explainability of algorithms,
- management of algorithmic bias,
- traceability of automated decisions,
- compliance with the General Data Protection Regulation (GDPR) and protection of sensitive health data.
The European Medicines Agency clearly states that AI systems should be used as decision-support tools, integrated within a risk-based governance framework. Final regulatory decisions must remain under human responsibility.
The forthcoming implementation of the European Artificial Intelligence Act (AI Act) will further strengthen the regulatory requirements applicable to AI systems used in medical devices and clinical research environments.
Artificial intelligence for clinical research: a powerful accelerator… under conditions
Artificial intelligence today represents a powerful accelerator for clinical research, capable of reducing timelines, improving data quality and facilitating faster patient access to therapeutic innovation.
However, effective deployment requires several conditions to be met:
- scientific validation of models,
- transparent and auditable use cases,
- adequate training of clinical and regulatory teams,
- early integration of AI within overall clinical development strategies.
For sponsors, CROs and institutional stakeholders, the key question is no longer whether AI will be used in clinical research, but how to integrate it responsibly, in full regulatory compliance and with demonstrable added value.
In this evolving landscape, artificial intelligence for clinical research are not merely technological trends, but structural drivers of transformation for the pharmaceutical ecosystem.
If you would like to receive regularly our articles, please subscribe here.
See article on the same subject : Artificial intelligence in clinical research: 7 real-world use cases already in practice
